UniCredit Knock-Out SNW/ DE000HB92HF9 /
2024-05-17 7:33:19 PM | Chg.-0.030 | Bid9:55:14 PM | Ask9:55:14 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.270EUR | -2.31% | 1.280 Bid Size: 4,000 |
1.300 Ask Size: 4,000 |
SANOFI SA INHABER ... | 76.9848 EUR | 2078-12-31 | Call |
GlobeNewswire
05-17
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and ...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
05-08
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
04-23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire
04-17
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...